Komori
Veritas In Silico (130A) · InitiativeAdvanced

Reduction of Stated Capital to Secure Flexibility and Agility in Capital Policy

First written in FY2024-Q1. 1 of 2 entries say "Achieved", first in FY2024-Q1. Latest entry: FY2025-H1.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2024-Q1 – FY2025-H12024: 120242025: 12025
Same theme, other companies

6 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 60 companies compared. The sentences above are computed from all 60.
Moved together

"Expansion into ASO, mRNA therapeutics, and ncRNA-targeted therapeutics" moved the same way as this thread, in the same document, in 2 of its 2 moves.

2★1
  1. ★This thread
  2. 1Expansion into ASO, mRNA therapeutics, and ncRNA-targeted therapeutics2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Veritas In Silico yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.